Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide

Additional Metadata
Persistent URL	doi.org/10.1210/jc.2014-4350, hdl.handle.net/1765/82650
Journal	Journal of Clinical Endocrinology and Metabolism
Organisation	Department of Internal Medicine
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Bengtsson, D., Schrøder, H. D., Andersen, M., Maiter, D., Berinder, K., Rasmussen, U. F., Rasmussen, Å. K., Johannsson, G., Hoÿbye, C., van der Lely, A.-J., Petersson, M., Ragnarsson, O.& Burman, P. (2015). Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. Journal of Clinical Endocrinology and Metabolism, 100(4), 1689–1698.https://doi.org/10.1210/jc.2014-4350

Publication